drugset / Trial / NCT03006874
Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to confirm the efficacy of CJ-12420, Once daily (QD), compared to esomeprazole in patients with erosive esophagitis classified as Los Angeles (LA) classification grades A to D at Week 8.
Timeline
- Start
- 2016-05-02
- Primary completion
- 2017-03-24
- Completion
- 2017-03-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Esomeprazole | Small molecule | 40 mg | Oral |
| Subject | Tegoprazan | Other / unclassified | 50 mg | Oral |
| Subject | Tegoprazan | Other / unclassified | 100 mg | Oral |